PCSA

3.38

4.64% 0.15

Handel nachbörslich: 3.38

Processa Pharmaceuticals Inc (PCSA)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$3.23

Offen:

$3.34

24-Stunden-Volumen:

93,743

Relative Volume:

0.09

Marktkapitalisierung:

$7.66M

Einnahmen:

Nettoeinkommen (Verlust:

$-12.88M

KGV:

-1.456

EPS:

-2.3215

Netto-Cashflow:

$-10.85M

1W Leistung:

+15.36%

1M Leistung:

-51.37%

6M Leistung:

-30.60%

1J Leistung:

-85.54%

1-Tages-Spanne:

$3.23

$3.4738

1-Wochen-Bereich:

$2.82

$3.4738

52-Wochen-Spanne:

$2.7375

$24.47

Processa Pharmaceuticals Inc Stock (PCSA) Company Profile

Firmenname

Processa Pharmaceuticals Inc

Sektor

Healthcare (1114)

Branche

Biotechnology (625)

Telefon

443-776-3133

Adresse

601 21ST STREET, SUITE 300, VERO BEACH

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

PCSA's Discussions on Twitter

Vergleichen Sie PCSA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PCSA Processa Pharmaceuticals Inc	3.38	7.32M	0	-12.88M	-10.85M	-2.3215
VRTX Vertex Pharmaceuticals Inc	468.38	113.87B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	776.54	80.22B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	406.40	52.56B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	803.74	49.31B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.07	37.37B	447.02M	-1.18B	-906.14M	-6.1812

Processa Pharmaceuticals Inc Stock (PCSA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-04-25	Eingeleitet	H.C. Wainwright	Buy

Processa Pharmaceuticals Inc Aktie (PCSA) Neueste Nachrichten

Jan 06, 2026

Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Lincoln Courier

Jan 06, 2026

Jan 05, 2026

Processa Pharmaceuticals completes enrollment of 20th patient in Phase 2 study - TipRanks

Jan 05, 2026

Processa Pharmaceuticals (PCSA) Advances in Phase 2 Cancer Study - GuruFocus

Jan 05, 2026

Processa Pharmaceuticals completes enrollment for NGC-Cap breast cancer study By Investing.com - Investing.com South Africa

Jan 05, 2026

Processa Pharmaceuticals completes enrollment for NGC-Cap breast cancer study - Investing.com Canada

Jan 05, 2026

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study - The Manila Times

Jan 05, 2026

New combo cancer drug reaches key test in advanced breast cancer trial - Stock Titan

Jan 05, 2026

Jan 01, 2026